Plain language summary
======================

It is important to understand the heterogeneous nature of GOLD B patient outcomes, because the majority of COPD patients are categorized as GOLD B. GOLD B patients according to the 2017 GOLD guidelines were at higher risk of exacerbations if they were older, had higher modified Medical Research Council and St George's Respiratory Questionnaire symptom scores, and a lower FEV~1~. Even though revised GOLD guidelines omitted FEV~1~ to assess COPD, FEV~1~ is an important factor to predict the outcomes.

Introduction
============

COPD patients exhibit heterogeneous features and different outcomes.[@b1-copd-13-3233] In the natural course of COPD, some patients remain in the same disease category, while some improve and others exhibit progression to more severe categories during follow-up.[@b2-copd-13-3233],[@b3-copd-13-3233] To treat patients effectively, it is important to identify factors associated with disease progression.

In the ECLIPSE cohort,[@b2-copd-13-3233] COPD patients were categorized as GOLD A, B, C, or D groups using the 2011 GOLD guidelines.[@b4-copd-13-3233] The most common category was GOLD D (40%); GOLD B contained 14% of all COPD patients at baseline. After 3 years, 36% of the GOLD B patients remained in the GOLD B group, but 35% progressed to GOLD D. In the COPDMAP cohort,[@b3-copd-13-3233] COPD patients were categorized as GOLD A, B, C, or D using the 2011 GOLD guidelines.[@b4-copd-13-3233] The most common category was GOLD D (59%); GOLD B contained 29% of the COPD patients at baseline. After 1 year, 68% of the GOLD B patients remained in the GOLD B group but 25% deteriorated to GOLD D.

Recently, the GOLD guidelines have been revised; COPD assessment now features analysis of respiratory symptoms and exacerbations alone, and not the FEV~1~, when assigning patients to various categories.[@b1-copd-13-3233] In the 2011 GOLD criteria,[@b4-copd-13-3233] GOLD B patients were defined by mild-to-moderate COPD (FEV~1~ ≥50%), exacerbation rate \<2/year, and a high symptom burden; cases with FEV~1~ values \<50% exhibiting the same exacerbation rate and symptoms were categorized as GOLD D. According to the revised 2017 GOLD criteria,[@b1-copd-13-3233] the former patients are categorized as GOLD B; however, the latter are categorized as GOLD B and not GOLD D. Patients with the same severe symptoms are now divided into GOLD B or D patients in terms of exacerbation risk, without reference to the FEV~1~. Identification of the characteristics of GOLD B and D patients, and of factors related to the progression from group B to group D, will help to clarify the exacerbation risk.

Most COPD patients in various populations are categorized as GOLD B.[@b5-copd-13-3233] Thus, knowledge of disease development over time in GOLD B patients is important. To date, the characteristics and natural course of GOLD B patients using the 2017 GOLD assessment criteria have not been described, and this is the aim of the present study. First, we examined the GOLD category changes from 2011 to 2017; second, we identified the baseline characteristics of 2017 GOLD B patients compared to those of GOLD D patients; and third, we identified the characteristics of GOLD B patients who remained GOLD B or progressed to GOLD D within 1 year.

Patients and methods
====================

Study design and patients
-------------------------

All patients were selected from the Korean COPD Subgroup Study (KOCOSS) (NCT02800499) cohort between December 2011 and July 2017. Data obtained at the first visit (baseline) and at 1 year were collected. In the KOCOSS, stable COPD patients are prospectively recruited from the outpatient clinics of 47 referral hospitals in Korea; enrollment commenced in December 2011 and is still ongoing. The inclusion criteria are as follows: diagnosis of COPD by a pulmonologist; age ≥40 years; cough, sputum production, and dyspnea; and a post-bronchodilator FEV~1~/FVC ratio ≤70% of the normal predicted value. Medical history-taking at baseline includes the frequency and severity of exacerbations in the previous 12 months, the body mass index (BMI), smoking status, patient-reported education level, medications taken (including those already prescribed for COPD), and comorbidities. The modified Medical Research Council (mMRC) dyspnea score is also recorded, as are the results of the COPD assessment test (CAT) and the COPD-specific version of St George's Respiratory Questionnaire (SGRQ). The 6-MWD is also performed. All data are recorded on electronic case report forms that are completed by physicians or trained nurses, and all patients are evaluated at 6-month intervals after initial examination. Blood tests are used to measure the levels of inflammatory markers and various chemicals and blood cell counts. The major exclusion criteria are as follows: asthma; other obstructive lung diseases, including bronchiectasis or tuberculous lung destruction; an inability to complete the pulmonary function test; myocardial infarction (MI) or a cerebrovascular event within the previous 3 months; pregnancy; rheumatoid disease; a malignancy; irritable bowel disease; and prescription of steroids for conditions other than COPD exacerbation within 8 weeks of enrollment. Exacerbations are defined as the worsening of any respiratory symptoms, including increased sputum volume, purulence, or advancing dyspnea, which require treatment with systemic corticosteroids, antibiotics, or both.[@b5-copd-13-3233]

Pulmonary functions and severity of airflow limitation
------------------------------------------------------

Spirometry was performed using standard techniques[@b6-copd-13-3233] at baseline and repeated every year during follow-up. The severity of airflow limitation was classified using post-bronchodilator FEV~1~ data alone, in accordance with both the 2011[@b4-copd-13-3233] and 2017 GOLD guidelines[@b1-copd-13-3233]; stage 1: FEV~1~ ≥80% predicted; stage 2 ≤50% to 80% predicted; stage 3 ≤30% to 50% predicted; and stage 4 \<30% predicted. The 6-MWD assessed functional capacity in accordance with the American Thoracic Society/European Respiratory Society guidelines.[@b7-copd-13-3233] A rapid decliner was defined as a patient with an FEV~1~ decline \>60 mL/year.[@b8-copd-13-3233]

Quality of life and dyspnea scores
----------------------------------

The SGRQ was administered to assess patient-perceived health status. The SGRQ is a 14-item questionnaire with symptom (SGRQ-S), activity (SGRQ-A), and impact (SGRQ-I) subscales. The total and three subscale scores were calculated as described in the SGRQ instruction manual.[@b9-copd-13-3233]

Dyspnea was evaluated using the mMRC dyspnea scale (a five-point scale on which higher scores indicate more severe dyspnea) and the CAT score. The CAT consists of eight items, each scored from 0 to 5, with higher scores indicating more severe symptoms.[@b1-copd-13-3233]

COPD assessment
---------------

All patients were categorized into four groups (GOLD A, B, C, or D) according to the 2011 GOLD criteria by assessing the FEV~1~, dyspnea scores, and exacerbation frequency.[@b4-copd-13-3233]

The patients were also categorized into four groups (GOLD A, B, C, or D) according to the 2017 GOLD recommendations by assessing symptoms and exacerbation frequency.[@b1-copd-13-3233]

Patients who were in the 2017 GOLD B at baseline and remained in that category for 1 year were defined as BB patients (stable), and those who deteriorated to GOLD D at 1 year were defined as BD patients (unstable).

Non-specific inflammatory markers
---------------------------------

We recorded the white blood cell (WBC) count, the proportion of neutrophils, the neutrophil/lymphocyte ratio (NLR), the C-reactive protein (CRP) level, and the erythrocyte sedimentation rate (ESR) to analyze differences in inflammatory marker levels between GOLD B and GOLD D patients and to explore the natural course of GOLD B patients.

Statistical analyses
--------------------

We compared the characteristics of GOLD B and GOLD D patients with 2017 GOLD classification. Differences between groups were analyzed using the two-sample *t*-test for continuous variables and the chi-squared or Fisher's exact test for categorical variables. We analyzed natural course of the 2017 GOLD B patients at 1 year later from baseline. We explored the redistribution of 2011 GOLD patients to the 2017 GOLD categories. After univariate analyses of the differences between groups BB and BD, multiple logistic regressions were used to adjust for potential confounding factors of GOLD B patients who progressed to GOLD D at 1 year. All tests were two-sided, and a *P*-value \<0.05 was considered to indicate significance. All statistical analyses were performed using SPSS software (version 24.0; IBM Corporation, Armonk, NY, USA).

Results
=======

Baseline characteristics according to the 2017 GOLD classification
------------------------------------------------------------------

We recruited 2,010 patients and their baseline characteristics are shown in [Table 1](#t1-copd-13-3233){ref-type="table"}. Of them, 1,261 (62.7%) were in the 2017 GOLD B group and 277 (13.8%) were in the 2017 GOLD D group. The GOLD B group contained more current smokers than did the GOLD D group (28.6% vs 19.9%, respectively, *P*=0.031). However, the smoking level did not differ between the groups. The historical rates of MI, chronic bronchitis, gastroesophageal reflux (GERD), and pneumonia were significantly lower in the GOLD B group than in the GOLD D group. Both FEV~1~ values and the 6-MWD were higher in the GOLD B group than in the GOLD D group. The mMRC, CAT, and SGRQ scores were lower in the GOLD B group than in the GOLD D group. The levels of inflammatory markers and mean WBC count, neutrophil level, NLR, CRP level, and ESR were lower in the GOLD B group than in the GOLD D group. The frequency of exacerbations during the previous 1 year was lower in the GOLD B group than in the GOLD D group.

The natural course of GOLD B patients according to the 2017 classifications
---------------------------------------------------------------------------

The GOLD A group contained 21.5% (n=433) of all patients and the GOLD C group contained 1.9% (n=39) ([Figure 1A](#f1-copd-13-3233){ref-type="fig"}). A total of 625 of the 1,261 GOLD B patients attended their 1-year follow-ups. Most GOLD B patients remained in group B at 1 year (n=432, 69.1%). Eighty-six patients (13.8%) progressed to GOLD D ([Figure 1B](#f1-copd-13-3233){ref-type="fig"}).

Patient distribution by GOLD classification
-------------------------------------------

Using the 2011 GOLD classification, 16.8% of the patients were in group A, 37.7% were in group B, 5.2% were in group C, and 34.4% were in group D ([Figure 2A](#f2-copd-13-3233){ref-type="fig"}). [Figure 2B](#f2-copd-13-3233){ref-type="fig"} shows the cumulative distribution of each 2011 GOLD group within each 2017 GOLD group. The 2017 GOLD A group included 2011 GOLD A (83.1%) and 2011 GOLD C (16.9%) patients. The 2017 GOLD B group was composed of 2011 GOLD B (63.7%) and 2011 GOLD D (36.3%) patients. The 2017 GOLD C and D groups were composed of 2011 GOLD C (100%) and D (100%) patients, respectively. Patients of 2011 GOLD C group were redistributed to the 2017 GOLD A (64.54%) and C (35.45%) groups. Patients in the 2011 GOLD D were redistributed to the 2017 GOLD B (61.63%) and D (38.36%) groups ([Figure 2C](#f2-copd-13-3233){ref-type="fig"}).

Progression of GOLD B patients to GOLD D using the 2017 classification
----------------------------------------------------------------------

The baseline characteristics of the BB and BD patients are shown in [Table 2](#t2-copd-13-3233){ref-type="table"}. The baseline FEV~1~ was significantly lower in BD patients compared to BB patients. Baseline age and the mMRC, SGRQ-S, SGRQ-A, SGRQ-I, and SGRQ total scores were significantly higher in BD patients than in BB patients. The percentage of patients with chronic bronchitis was higher in the BD patients (*P*=0.003). Inflammatory marker levels did not differ significantly between the BB and BD patients, with the exception of the WBC count ([Table 2](#t2-copd-13-3233){ref-type="table"}).

In multivariate analysis, age, the mMRC and SGRQ-S scores, and the % predicted FEV~1~ were significantly associated with progression from GOLD B to GOLD D at 1 year after adjusting for sex, BMI, the presence of chronic bronchitis, the SGRQ-A, SGRQ total and CAT scores, a history of GERD, and exacerbation frequency at baseline ([Table 3](#t3-copd-13-3233){ref-type="table"}).

Changes in FEV~1~
-----------------

The mean change in FEV~1~ from baseline over 1 year was an increase of 39 mL in the BB patients and a reduction of 62 mL in the BD patients (*P*=0.005) ([Figure 3A](#f3-copd-13-3233){ref-type="fig"}). Thirty-one patients (45.6%) exhibited declines \>60 mL over 1 year in the BD group, as did 112 BB patients (33%) (*P*=0.045) ([Figure 3B](#f3-copd-13-3233){ref-type="fig"}).

Discussion
==========

We found that older age, a higher level of respiratory symptoms, poorer health status, and a lower % predicted FEV~1~ at baseline were associated with progression from GOLD B to GOLD D over 1 year with the 2017 GOLD classification, similar to the results when the 2011 GOLD classification was employed.[@b3-copd-13-3233] This is the first report to identify GOLD B patients who progressed to GOLD D and the factors associated with such progression, using the 2017 GOLD guidelines. Most GOLD B patients retained GOLD B at 1 year, but 13.8% progressed to GOLD D. Although homogenous terms of the mMRC scale, CAT scores, and the exacerbation frequency were used to assess the GOLD B group, the natural courses of GOLD B patients were heterogeneous.

We found that older GOLD B patients progressed to GOLD D more readily. The exacerbation rates increase with age;[@b10-copd-13-3233] lung function declines with aging in never smokers,[@b11-copd-13-3233] and this decline is accelerated in smokers.[@b12-copd-13-3233] The decline in FEV~1~ accelerates nonlinearly after the age of 70 years.[@b13-copd-13-3233] In our cohort, the mean age of all patients was 70 years. GOLD D patients were 1 year older than GOLD B patients, and BD patients were 2 years older than BB patients. Older COPD patients may be at an increased risk of exacerbation, as are patients with greater airflow limitations. Aging accelerates the decline in lung function and contributes to COPD deterioration.

In our study, the mMRC, SGRQ symptom, activity, and total scores were higher in GOLD B patients who deteriorated than in those who did not. In the COPDMAP cohort, the CAT, SGRQ activity, and total scores were higher in GOLD B patients who deteriorated.[@b3-copd-13-3233] In the 2017 GOLD assessment, the only difference between GOLD B and D patients is the exacerbation frequency;[@b1-copd-13-3233] deterioration from GOLD B to GOLD D implies an increased exacerbation frequency. In the Hokkaido COPD cohort, patients who experienced exacerbations exhibited reduced lung function, more dyspnea, and a higher SGRQ total score compared to patients who did not experience exacerbations.[@b14-copd-13-3233] Impaired health-related quality of life induced exacerbations, but the influential SGRQ domain in exacerbations differed between cohorts. In multivariate analysis, the symptom domain score was significantly associated with exacerbations in the KOCOSS cohort, while the activity domain score was significantly associated with exacerbations in the Hokkaido COPD cohort.[@b14-copd-13-3233] Dyspnea is one of the major forms of exacerbation, reducing physical activity and health status. It is possible that more severe symptoms or symptom-related health issues increase exacerbations.

Patients with fewer symptoms, a lower risk of exacerbations, and FEV~1~ values \<50% were categorized as GOLD C in the 2011 classification. However, using the 2017 classification, those with fewer symptoms and a lower risk of exacerbations are categorized as GOLD A regardless of FEV~1~ status. The omission of FEV~1~ in terms of COPD assessment redistributes some GOLD C patients to the GOLD A group and some GOLD D patients to the GOLD B group. Although the 2017 GOLD classification does not use the FEV~1~, the FEV~1~ significantly influenced the progression of GOLD B patients to GOLD D in our study, similar to what is found when FEV~1~ is used to assess COPD.[@b3-copd-13-3233] A lower FEV~1~ was significantly related to increased exacerbations that redistributed GOLD B patients to GOLD D after 1 year. An FEV~1~ decline increased the risk of exacerbation. In the ECLIPSE cohort, the rate of exacerbations requiring hospitalization increased as the airflow limitation rose.[@b10-copd-13-3233] Recent study found that the 2017 GOLD classification did not predict mortality more accurately than the 2011 classification.[@b15-copd-13-3233] Although, the current GOLD criteria do not use the FEV~1~ to assess COPD, we intend to retain our focus on the FEV~1~ to assess, treat, and predict outcomes of COPD.

The annual lung function declines were 44, 48, 38, and 39 mL in groups A--D of the UPLIFT trial, respectively.[@b16-copd-13-3233] The FEV~1~ declines did not differ among the groups (33.4, 38.0, 30.2, and 31.9, respectively);[@b17-copd-13-3233] these data were derived using the 2011 GOLD classification. In our cohort, rapid decliners were significantly more common in the deteriorating BD patients than in the stable BB patients. The frequency of rapid decliners in GOLD B patients was lower (34%, data not shown) in our cohort than in the COPDMAP cohort (58.7%).[@b3-copd-13-3233] Uniquely, we found a prominent difference in lung function decline between deteriorating BD and stable BB patients at 1 year. In the COPDMAP cohort, the changes in FEV~1~ from baseline were −80 mL in a stable group and −120 mL in an unstable group. In our cohort, BB patients (defined as "stable" in the COPDMAP cohort) exhibited an increase in FEV~1~ of 39 mL at 1 year, and BD patients (defined as "unstable" in the COPDMAP cohort) showed a decrease of 62 mL. Lung function decline in our cohort differed from that of the COPDMAP cohort.

The limitations of our study include the low percentage of females and high percentage of dropouts during longitudinal follow-up. Nonetheless, the KOCOSS cohort is representative of real-world study and reflects real-world practice. We examined the characteristics of GOLD B patients and the natural course of the GOLD B patients in a large patient sample.

Conclusion
==========

Most COPD patients are GOLD B, and most GOLD B patients remained in group B after 1-year follow-up on application of the 2017 criteria. GOLD B patients who progressed to GOLD D had higher mMRC and SGRQ symptom scores and lower FEV~1~ values than did those who remained GOLD B. This means that GOLD B patients who are highly symptomatic and have more severe airflow limitations are at high risk of exacerbations. We suggest that such patients require early treatment and close monitoring.
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![The natural courses of GOLD B patients over 1 year.\
**Notes:** (**A**) The distribution of COPD groups at baseline according to the 2017 GOLD classifications (n=2,010). Of the 1,261 GOLD B patients at baseline (**A**), 625 patients were attended 1-year follow-up and 432 patients (69.1%) of them remained in GOLD B at 1 year (**B**).](copd-13-3233Fig1){#f1-copd-13-3233}

![Distribution of COPD groups by GOLD classifications.\
**Notes:** (**A**) Distributions of COPD groups by reference to the 2011 GOLD classifications. (**B**) Cumulative patient numbers in the various COPD groups using the 2011 and 2017 GOLD criteria. (**C**) Changes in groups of COPD patients according to the GOLD classifications.](copd-13-3233Fig2){#f2-copd-13-3233}

![(**A**) Changes in FEV~1~ from baseline to 1 year in groups BB and DD. (**B**) More patients in group BD than in group BB exhibited a rapid FEV~1~ decline (\>60 mL).\
**Notes:** \**P*=0.045; \*\**P*=0.040. BB, GOLD B patients who remained GOLD B; BD, GOLD B patients who degenerated to GOLD D.](copd-13-3233Fig3){#f3-copd-13-3233}

###### 

Baseline characteristics of COPD groups B and D with 2017 classification

  Variables                                Total           GOLD B          GOLD D          *P*-value
  ---------------------------------------- --------------- --------------- --------------- -----------
                                                                                           
  Subjects                                 2,010           1,261 (62.7)    277 (13.8)      
  Mean age, years (SD)                     70.1±7.9        70.1±8.0        71.0±7.7        0.102
  Males                                    1,806 (89.9)    1,379 (92.1)    76 (87.5)       0.024
  Current smokers                          542 (26.7)      358 (28.6)      55 (19.9)       0.003
  Smoking, pack/years (SD)                 43.27 (25.4)    43.28 (25.2)    44.27 (26.7)    0.586
  BMI, kg/m^2^ (SD)                        22.91 (3.3)     22.9 (3.4)      22.2 (3.3)      0.003
  Comorbidities                                                                            
   HTN                                     785 (39.3)      491 (39.2)      111 (40.2)      0.758
   DM                                      327 (16.4)      200 (15.9)      50 (18.1)       0.378
   HF                                      67 (3.4)        45 (3.6)        16 (5.8)        0.092
   MI                                      107 (5.4)       57 (4.6)        22 (8.0)        0.020
   Chronic bronchitis                      144 (11.4)      45 (16.2)       21 (24.4)       0.027
   GERD                                    185 (9.3)       107 (8.6)       39 (14.1)       0.004
   Pneumonia                               283 (14.2)      161 (12.9)      73 (26.7)       \<0.001
  Lung function                                                                            
   FEV~1~, L (SD)                          1.55 (0.57)     1.51 (0.54)     1.23 (0.50)     \<0.001
   FEV~1~ % predicted (SD)                 57.8 (18.9)     57.3 (19.0)     47.7 (16.7)     \<0.001
   FVC, L (SD)                             3.12 (0.81)     3.08 (0.80)     2.79 (0.77)     \<0.001
   FVC % predicted (SD)                    81.9 (17.6)     81.7 (17.7)     81.7 (17.7)     \<0.001
   Reversibility, % (SD)                   7.0 (9.5)       7.2 (9.5)       6.2 (0.2)       0.124
   Reversibility, mL (SD)                  77.2 (16.9)     77.3 (15.8)     57.2 (16.2)     0.061
   6-MWD, m (SD)                           381.1 (116.6)   375.2 (110.3)   345.2 (125.4)   \<0.001
   mMRC score (SD)                         1.4 (0.9)       1.5 (0.8)       2.0 (0.9)       \<0.001
   CAT score (SD)                          14.9 (37.9)     17.1 (6.4)      20.0 (7.9)      \<0.001
   SGRQ-S score (SD)                       43.3 (20.5)     45.4 (19.3)     57.4 (19.0)     \<0.001
   SGRQ-A score (SD)                       44.2 (23.4)     47.5 (21.9)     59.9 (23.5)     \<0.001
   SGRQ-I score (SD)                       22.9 (19.4)     24.9 (18.7)     36.5 (22.3)     \<0.001
   SGRQ total score (SD)                   32.6 (18.7)     35.1 (17.4)     47.1 (20.0)     \<0.001
  Inflammatory marker levels                                                               
   WBC/µL (SD)                             7,619 (2,400)   7,612 (2,400)   8,499 (3,370)   \<0.001
   Neutrophils, % (SD)                     58.8 (12.3)     58.6 (12.1)     62.4 (14.6)     \<0.001
   NLR (SD)                                2.75 (3.53)     2.58 (3.01)     4.09 (5.64)     \<0.001
   CRP, mg/L (SD)                          2.89 (8.07)     2.45 (6.48)     5.11 (12.42)    0.028
   ESR, mm/h (SD)                          17.82 (17.73)   17.88 (18.04)   26.35 (22.0)    \<0.001
   Exacerbations, n/previous 1 year (SD)   0.64 (1.81)     0.08 (0.30)     3.77 (3.21)     \<0.001

**Note:**

Data are presented as number (%) unless otherwise specified.

**Abbreviations:** BMI, body mass index; CAT score, COPD assessment test score; CRP, C-reactive protein; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; GERD, gastroesophageal reflux; HF, heart failure; HTN, hypertension; MI, myocardial infarction; mMRC score, modified Medical Research Council score; NLR, neutrophil/lymphocyte ratio; SD, standard deviation; SGRQ score, St George's Respiratory Questionnaire score; SGRQ-A score, SGRQ activity score; SGRQ-I score, SGRQ impact score; SGRQ-S score, SGRQ symptom score; WBC, white blood cell.

###### 

Comparison of baseline characteristics between GOLD B patients who remained GOLD B (BB) and those who degenerated to GOLD D (BD), at 1 year post-diagnosis

  Variables                                BB              BD              *P*-value
  ---------------------------------------- --------------- --------------- -----------
                                                                           
  Subjects                                 432 (69.1)      86 (13.8)       
  Age, years (SD)                          70.1 (7.6)      72.2 (6.8)      0.021
  Male                                     397 (92.3)      76 (88.4)       0.282
  Current smokers                          121 (28)        19 (22.1)       0.289
  Smoking commencement age, years (SD)     21.2 (5.3)      21.1 (6.4)      0.871
  Smoking, pack/years (SD)                 43.0 (24.5)     47.2 (27.6)     0.184
  History of family smoking, n (%)         88 (20.9)       19 (22.6)       0.717
  BMI, kg/m^2^ (SD)                        22.8 (3.4)      22.8 (3.1)      0.992
  Comorbidities                                                            
   HTN                                     172 (39.9)      42 (48.8)       0.125
   DM                                      69 (16.0)       14 (16.3)       0.950
   PVD                                     11 (2.6)        1 (1.2)         0.700
   HF                                      13 (3.0)        2 (2.3)         0.856
   MI                                      16 (3.7)        2 (2.3)         0.750
   Chronic bronchitis                      52 (12.0)       21 (24.4)       0.003
   GERD                                    55 (13.3)       11 (13.3)       0.986
   Pneumonia                               60 (14.0)       14 (16.3)       0.614
   Hyperlipidemia                          47 (10.9)       8 (9.6)         0.728
  Pulmonary function                                                       
   FEV~1~, L (SD)                          1.43 (0.46)     1.21 (0.39)     \<0.001
   FEV~1~ % predicted (SD)                 56.4 (17.8)     48.1 (16.3)     \<0.001
   FVC, L (SD)                             2.98 (0.74)     2.82 (0.77)     0.073
   FVC % predicted (SD)                    81.9 (17.2)     78.6 (18.9)     0.110
   Reversibility, % (SD)                   7.7 (9.2)       6.6 (8.8)       0.308
   Reversibility, mL (SD)                  80.2 (150.4)    77.1 (101.1)    0.859
   6-MWD, m (SD)                           365.3 (104.7)   352.2 (116.7)   0.338
   mMRC score (SD)                         1.6 (0.7)       2.0 (0.8)       \<0.001
   CAT total score (SD)                    17.9 (6.4)      19.2 (7.6)      0.151
   SGRQ-S score (SD)                       45.9 (18.4)     56.6 (18.5)     \<0.001
   SGRQ-A score (SD)                       51.6 (20.8)     59.2 (24.3)     0.009
   SGRQ-I score (SD)                       28.2 (18.9)     32.5 (22.1)     0.098
   SGRQ total score (SD)                   38.3 (17.0)     44.6 (20.4)     0.008
  Inflammatory marker levels                                               
   WBC/µL (SD)                             7.490 (2.210)   8.120 (2.590)   0.028
   Neutrophils, % (SD)                     59.2 (12.1)     61.6 (13.9)     0.109
   NLR (SD)                                2.59 (1.96)     3.74 (8.70)     0.267
   CRP, mg/L (SD)                          2.05 (6.44)     1.72 (3.07)     0.787
   ESR, mm/h (SD)                          17.71 (15.07)   20.46 (20.32)   0.348
   Exacerbations, n/previous 1 year (SD)   0.09 (0.29)     0.17 (0.38)     0.070

**Note:**

Data are presented number (%) unless otherwise specified.

**Abbreviations:** BMI, body mass index; CAT, COPD assessment test; CRP, C-reactive protein; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; GERD, gastroesophageal reflux; HF, heart failure; HTN, hypertension; MI, myocardial infarction; mMRC score, modified Medical Research Council score; NLR, neutrophil/lymphocyte ratio; PVD, peripheral vascular disease; SD, standard deviation; SGRQ score, St George's Respiratory Questionnaire score; SGRQ-S score, SGRQ symptom score; SGRQ-A score, SGRQ activity score; SGRQ-I score, SGRQ impact score; WBC, white blood cell.

###### 

Multivariate analysis of baseline factors associated with progression from GOLD B to GOLD D over 1 year

  Variables            *P*-value   Exp (B)   95% CI
  -------------------- ----------- --------- --------------
                                             
  Age                  0.014       1.049     1.010--1.089
  mMRC score           0.005       1.617     1.159--2.259
  SGRQ-S score         0.001       1.024     1.010--1.039
  FEV~1~ % predicted   0.013       0.979     0.962--0.995

**Notes:** Adjusted for age, gender, BMI, chronic bronchitis status, SGRQ-A score, SGRQ total score, CAT score, GERD status, and exacerbation frequency at baseline. *P*-values \<0.05 are statistically significant in accordance with Logistic regression analysis.

**Abbreviations:** BMI, body mass index; CAT, COPD assessment test; GERD, gastroesophageal reflux; mMRC score, modified Medical Research Council score; SGRQ-A score, St George's Respiratory Questionnaire activity score; SGRQ-S score, SGRQ symptom score.
